Related Experiment Video

Updated: Jul 9, 2026

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

[CARD15 mutations are poorly related to Crohn's disease phenotypes in Asturias]

L Rodrigo1, J Martínez-Borra, J A Garrote

  • 1Servicios de Aparato Digestivo, Hospital Universitario Central de Asturias, Oviedo. lrodrigos@terra.es

Revista Espanola De Enfermedades Digestivas
|December 7, 2007
PubMed

Insights

Genetic susceptibility to Crohn's disease (CD) was investigated for CARD15 gene mutations in Asturias. The study found no significant association between CARD15 polymorphisms and CD development or clinical characteristics in this population.

Area of Science:

  • Genetics
  • Gastroenterology
  • Molecular Biology

Context:

  • The CARD15 gene is implicated in Crohn's disease (CD) susceptibility.
  • Previous studies show geographic and ethnic variations in CARD15 mutation prevalence.
  • Understanding genetic factors in CD is crucial for personalized medicine.

Purpose:

  • To determine the prevalence of CARD15 gene mutations in CD patients from Asturias, Spain.
  • To investigate the correlation between CARD15 polymorphisms and CD phenotypes.
  • To analyze the contribution of CARD15 mutations to disease characteristics and progression.

Summary:

  • A study analyzed CARD15 mutations (R702W, G908R, L1007fs) in 216 CD patients and 86 controls from Asturias.
  • Carrier frequencies for CARD15 mutations were similar in CD patients and controls.
  • No significant relationship was found between CARD15 mutations and CD phenotypes based on the Vienna classification.

Impact:

  • This research suggests that factors beyond CARD15 genetics, such as environmental influences, play a significant role in CD pathogenesis in the studied population.
  • Findings contribute to the understanding of CD genetic epidemiology in Spain.
  • Highlights the need for comprehensive etiological models for Crohn's disease.
Abstract

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...